- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04415190
the Impact of Early Palliative Care on the Survival of Locally Advanced and / or Metastatic Cholangiocarcinoma Patients
June 2, 2020 updated by: Anthony LOPEZ, Central Hospital, Nancy, France
Multicenter Retrospective Study Evaluating the Impact of Early Palliative Care on the Survival of Patients With Locally Advanced and / or Metastatic Cholangiocarcinoma (CCK)
The prognosis for cholangiocarcinoma is bad.
Potentially, early management by a palliative care team could increase overall survival.
We will also assess whether early management by a palliative care team could impact progression-free survival, the place of death and the date of the last chemotherapy, in particular to avoid unnecessary chemotherapy cures in an imminent end of life
Study Overview
Study Type
Observational
Enrollment (Anticipated)
150
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Vandœuvre-lès-Nancy, France, 54500
- Lopez
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Cholangiocarcinoma metastatic or locally advanced
Description
Inclusion Criteria:
- Age> 18 years old
- intra- or extra-hepatic CCK or histologically proven vesicular adenocarcinoma
- Locally advanced and / or metastatic disease from the start or recurrent
- Initial diagnosis or recurrence between 1/01/2013 and 31/12/2019
Exclusion Criteria:
- <18 years old
- death less than one week after the diagnostic
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
cholangiocarcinoma with early palliative care
|
early palliative care
|
|
cholangiocarcinoma without early palliative care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Global survival
Time Frame: baseline
|
Global survival from the diagnosis (to the death or because of lost to follow up)
|
baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Anthony Lopez, CHRU Nancy
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
June 1, 2020
Primary Completion (ANTICIPATED)
June 1, 2020
Study Completion (ANTICIPATED)
December 31, 2020
Study Registration Dates
First Submitted
May 29, 2020
First Submitted That Met QC Criteria
June 2, 2020
First Posted (ACTUAL)
June 4, 2020
Study Record Updates
Last Update Posted (ACTUAL)
June 4, 2020
Last Update Submitted That Met QC Criteria
June 2, 2020
Last Verified
May 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019PI274
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cholangiocarcinoma
-
Mayo ClinicTerminatedStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Cholangiocarcinoma | Refractory Cholangiocarcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Advanced CholangiocarcinomaUnited States
-
University of Kansas Medical CenterNational Cancer Institute (NCI)Active, not recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Cholangiocarcinoma | Locally Advanced Cholangiocarcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Recurrent CholangiocarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic Cholangiocarcinoma | Oligometastatic Intrahepatic CholangiocarcinomaUnited States
-
RedHill Biopharma LimitedCompletedCholangiocarcinoma | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Perihilar | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, IntrahepaticUnited States
-
RedHill Biopharma LimitedNo longer availableCholangiocarcinoma | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Perihilar | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic
-
M.D. Anderson Cancer CenterActive, not recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic CholangiocarcinomaUnited States
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH); CelgeneCompletedResectable Cholangiocarcinoma | Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8United States
-
Emory UniversityNational Cancer Institute (NCI)WithdrawnStage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Resectable Intrahepatic Cholangiocarcinoma | Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8 | Stage I Intrahepatic Cholangiocarcinoma AJCC v8United States
-
AIO-Studien-gGmbHServierCompletedCholangiocarcinoma Non-resectable | Cholangiocarcinoma of the Gallbladder | Cholangiocarcinoma Metastatic | Cholangiocarcinoma AdvancedGermany
-
National Cancer Institute (NCI)CompletedStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Gallbladder Carcinoma | Metastatic Cholangiocarcinoma | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable CholangiocarcinomaUnited States
Clinical Trials on early palliative care
-
Al Al Bayt University, JordanKing Hussein Cancer CenterNot yet recruitingCancer | Palliative Care, Patient Care
-
Istituto Scientifico Romagnolo per lo Studio e...Completed
-
Pippa HawleyCompleted
-
McMaster UniversitySt. Joseph's Healthcare HamiltonTerminated
-
Azienda Ospedaliero-Universitaria di ParmaRegione Emilia-RomagnaCompletedGastric Cancer | Pancreatic Cancer | Non-small Cell Lung Cancer | Biliary Tract Cancer
-
University Health Network, TorontoMyeloma Canada; The Leukemia and Lymphoma Society of CanadaRecruitingLymphoma, B-Cell | Multiple Myeloma | B Cell Lymphoma | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Multiple Myeloma Progression | Multiple Myeloma Stage III | Aggressive LymphomaCanada
-
Azienda USL Reggio Emilia - IRCCSTerminated
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedDepression | Small Cell Lung Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Malignant Mesothelioma | Non-small Cell Lung Cancer | Liver Cancer | Anxiety Disorder | Extrahepatic Bile Duct CancerUnited States
-
University Hospital, GenevaSwiss National Science FoundationCompleted
-
Inna Chen, MDOdense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaboratorsActive, not recruitingPancreatic CancerDenmark